Warning! GuruFocus detected
3 Severe warning signs
with NG9.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
NeoGenomics Inc
NAICS : 541714
SIC : 8734
ISIN : US64049M2098
Description
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.64 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.67 | |||||
| Debt-to-EBITDA | -400.62 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.15 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.9 | |||||
| 3-Year FCF Growth Rate | 29.2 | |||||
| 3-Year Book Growth Rate | -7.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 77.36 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 11.63 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.85 | |||||
| 9-Day RSI | 23.61 | |||||
| 14-Day RSI | 28.58 | |||||
| 3-1 Month Momentum % | -45.11 | |||||
| 6-1 Month Momentum % | -21.07 | |||||
| 12-1 Month Momentum % | -29.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.98 | |||||
| Quick Ratio | 1.89 | |||||
| Cash Ratio | 1.28 | |||||
| Days Inventory | 23.43 | |||||
| Days Sales Outstanding | 79.57 | |||||
| Days Payable | 18.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | -0.17 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 43.92 | |||||
| Operating Margin % | -12.94 | |||||
| Net Margin % | -11.92 | |||||
| FCF Margin % | -5.12 | |||||
| ROE % | -8.57 | |||||
| ROA % | -4.77 | |||||
| ROIC % | -6.53 | |||||
| 3-Year ROIIC % | 182.81 | |||||
| ROC (Joel Greenblatt) % | -26.04 | |||||
| ROCE % | -5.15 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 47.04 | |||||
| PE Ratio without NRI | 91.2 | |||||
| PS Ratio | 1.75 | |||||
| PB Ratio | 1.3 | |||||
| Price-to-Tangible-Book | 29.4 | |||||
| Price-to-Operating-Cash-Flow | 165.82 | |||||
| EV-to-EBIT | -17.17 | |||||
| EV-to-EBITDA | -841.74 | |||||
| EV-to-Revenue | 1.93 | |||||
| EV-to-Forward-Revenue | 2.49 | |||||
| EV-to-FCF | -37.37 | |||||
| Price-to-GF-Value | 0.54 | |||||
| Price-to-Projected-FCF | 3.89 | |||||
| Price-to-Median-PS-Value | 0.45 | |||||
| Price-to-Graham-Number | 10.81 | |||||
| Earnings Yield (Greenblatt) % | -5.82 | |||||
| FCF Yield % | -2.91 | |||||
| Forward Rate of Return (Yacktman) % | -8.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NeoGenomics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 612.032 | ||
| EPS (TTM) (€) | -0.573 | ||
| Beta | 0.93 | ||
| 3-Year Sharpe Ratio | 0.11 | ||
| 3-Year Sortino Ratio | 0.2 | ||
| Volatility % | 65.58 | ||
| 14-Day RSI | 28.58 | ||
| 14-Day ATR (€) | 0.393929 | ||
| 20-Day SMA (€) | 8.67 | ||
| 12-1 Month Momentum % | -29.26 | ||
| 52-Week Range (€) | 7.35 - 17.7 | ||
| Shares Outstanding (Mil) | 128.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NeoGenomics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeoGenomics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NeoGenomics Inc Frequently Asked Questions
What is NeoGenomics Inc(STU:NG9)'s stock price today?
The current price of STU:NG9 is €7.35. The 52 week high of STU:NG9 is €17.70 and 52 week low is €7.35.
When is next earnings date of NeoGenomics Inc(STU:NG9)?
The next earnings date of NeoGenomics Inc(STU:NG9) is 2025-04-30 Est..
Does NeoGenomics Inc(STU:NG9) pay dividends? If so, how much?
NeoGenomics Inc(STU:NG9) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers